AbbVie Acquires Syndesi Therapeutics
Strengthening Neuroscience Portfolio
10-Mar-2022 -
AbbVie announced it has completed the acquisition of Syndesi Therapeutics SA, which will help to expand AbbVie's neuroscience portfolio. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. ...
AbbVie
acquisitions
Alzheimer's disease
+3